Werewolf Therapeutics (NASDAQ:HOWL) Trading Down 3.6%

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report)'s share price was down 3.6% during mid-day trading on Thursday . The stock traded as low as $2.13 and last traded at $2.16. Approximately 128,007 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 255,839 shares. The stock had previously closed at $2.24.

Wall Street Analysts Forecast Growth

HOWL has been the topic of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Werewolf Therapeutics in a research report on Tuesday, July 2nd. Wedbush reaffirmed an "outperform" rating and set a $9.00 target price on shares of Werewolf Therapeutics in a research report on Monday, June 3rd. Finally, JMP Securities reissued a "market outperform" rating and set a $12.00 price target on shares of Werewolf Therapeutics in a research report on Wednesday, June 26th.

Werewolf Therapeutics Trading Up 8.3 %

The stock has a market capitalization of $102.26 million, a P/E ratio of -2.14 and a beta of 0.46. The stock's 50 day moving average price is $2.30 and its 200-day moving average price is $4.14. The company has a quick ratio of 12.13, a current ratio of 12.13 and a debt-to-equity ratio of 0.24.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $2.00 million. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 48.25%. As a group, equities research analysts expect that Werewolf Therapeutics, Inc. will post -1.64 earnings per share for the current year.

Institutional Trading of Werewolf Therapeutics

Institutional investors have recently modified their holdings of the company. Point72 DIFC Ltd acquired a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth $34,000. Rhumbline Advisers acquired a new stake in Werewolf Therapeutics in the second quarter worth about $79,000. Lighthouse Investment Partners LLC purchased a new stake in shares of Werewolf Therapeutics during the fourth quarter worth about $87,000. American Century Companies Inc. grew its stake in shares of Werewolf Therapeutics by 50.7% during the second quarter. American Century Companies Inc. now owns 37,634 shares of the company's stock worth $92,000 after acquiring an additional 12,656 shares during the last quarter. Finally, Murchinson Ltd. acquired a new position in shares of Werewolf Therapeutics during the second quarter valued at about $152,000. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.